You just read:

Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome

News provided by

Therabron Therapeutics, Inc.

23 Jan, 2017, 16:33 ET